Barbara Breznik presented research work at the EACR congress in Rotterdam (10-13 June) in a form of poster presentation. She presented work, entitled »Utilizing translational platform GlioBank to identify novel molecular signatures of glioblastoma progression«.

 Glioblastoma (GBM) is one of the most lethal solid tumors in humans. Currently, GBM is considered incurable and there is a lack of progress in identifying clinically relevant biomarkers and effective therapeutic options. The aim of the study was to establish a translational platform in Slovenia to centrally collect biological material and all relevant clinical and research data and use GlioBank datasets to determine the molecular characteristics of GBM and identify biomarkers associated with poor GBM survival.